Somatic mutations precede acute myeloid leukemia years before diagnosis
Pinkal M. Desai +11 more
semanticscholar +1 more source
Data‐Independent Acquisition Mass Spectrometry in Tumor Classification and Cancer Biomarker Research
Abstract Cancer treatment is far from optimal also because current classification systems do not reflect the complex molecular status of the tumor and its phenotype in sufficient detail. To construct molecular tumor classifiers, omics tools provide complex molecular data reflecting many aspects from genotype to phenotype.
Jan Simonik +3 more
wiley +1 more source
Antiapoptotic BCL2 family proteins BCL-XL and MCL1 as factors predicting resistance against venetoclax plus azacitidine for patients with newly diagnosed acute myelogenous leukemia. [PDF]
Kamihara Y +12 more
europepmc +1 more source
Using data from the Global Burden of Disease Study 2021, we systematically assessed leukemia prevalence and disability‐adjusted life years (DALYs) across 204 countries and territories from 1990 to 2021, stratified by subtype, demographics, and risk factors.
Yuping Wu +8 more
wiley +1 more source
Comparison of changes in blood cells and hemostatic biomarkers in mouse xenograft models of acute myeloid leukemia and acute promyelocytic leukemia. [PDF]
Archibald SJ +5 more
europepmc +1 more source
Machine Learning for Predictive Modeling in Nanomedicine‐Based Cancer Drug Delivery
The integration of AI/ML into nanomedicine offers a transformative approach to therapeutic design and optimization. Unlike conventional empirical methods, AI/ML models (such as classification, regression, and neural networks) enable the analysis of complex clinical and formulation datasets to predict optimal nanoparticle characteristics and therapeutic
Rohan Chand Sahu +3 more
wiley +1 more source
Blinatumomab-Related Lineage Switch of KMT2A/AFF1-Rearranged B-Lymphoblastic Leukemia to B/Myeloid Mixed-Phenotype Acute Leukemia and Myeloid Sarcoma Causing Spinal Cord Compression. [PDF]
Fan X +5 more
europepmc +1 more source
CRISPR Enabled Precision Oncology: From Gene Editing to Tumor Microenvironment Remodeling
CRISPR technology has progressed from a prokaryotic immune system to a diverse suite of editing platforms, including Cas nucleases, base and prime editors, and RNA‐targeting enzymes. These advances enable precise genomic and epigenomic interventions, high‐throughput functional screening, and immune engineering.
Kailai Li +8 more
wiley +1 more source

